Greco-Hainsworth Centers for Research

Named to honor Drs. Anthony Greco and John Hainsworth, the Greco-Hainsworth Centers for Research is Tennessee Oncology’s dedicated clinical research division.

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Dr. Sara Nunnery, Director of Breast Cancer Research, joins an expert panel to discuss key questions and future directions in ESR1-mutated breast cancer.

Watch the full discussion🔗 https://t.co/0N4kLnXxj7

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Today, we recognize World Cancer Research Day and the researchers, physicians, and patients helping advance the future of cancer care. 🔬

#WorldCancerResearchDay #GHCR #TennesseeOncology #CancerResearch #ClinicalTrials

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Dr. Wade Iams, Director of Lung Cancer Research at GHCR, discusses duration of response across ROS1 inhibitor trials and what treatment response may reveal about disease control in ROS1+ NSCLC.

Watch here 🔗 https://t.co/a9y6YfrCjn

#NSCLC #ROS1

[Katy Beckermann @katy_beckermann]

Most of what we know about advanced kidney cancer comes from clinical trials while helpful we recognize it may not represent broader patient populations.

Excited to be heading for San Diego this week for Bridging the Gaps in GU Oncology, a new OncLive needs-assessment meeting built this idea identifying the gaps in GU oncology.

I'm speaking on belzutifan, where trial patient and clinic patient diverge most: selection, monitoring burden, supportive care on trial vs FDA labels.

Thanks to @OncLive and @DrRanaMcKay and @TDorffOnc for hosting!

#KidneyCancer #BladderCancer #ProstateCancer #GUonc

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

What can breast and colorectal cancer teach us about minimal residual disease (MRD)?

Experts discuss insights across tumor types and the potential role of MRD in guiding treatment decisions.

Watch the full discussion 🔗 https://t.co/EGxh3uwOR7

#CancerResearch #GHCR

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Dr. Wade Iams, Director of Lung Cancer Research at GHCR, discusses intracranial control in ROS1+ NSCLC and how targeted treatment strategies may help delay brain radiation in select patients.

Watch here🔗 https://t.co/CaheAyCkIF

#LungCancer #NSCLC #ROS1

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Dr. @SaraNunneryMD, Director of Breast Cancer Research, shares insights on the evolving endocrine treatment landscape for ESR1-mutated, ER+/HER2-negative metastatic breast cancer.

Watch to learn more 🔗 https://t.co/7mVn4MDJJR

#BreastCancer #ESR1 #GHCR

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Dr. Brian Grieb, Director of Gastrointestinal Research at GHCR, discusses how combining biomarkers can help guide treatment decisions and provide a more comprehensive approach to treatment selection.

Watch the full discussion 🔗 https://t.co/eXbo4N0qSt

#GHCR #CancerResearch

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Dr. @SaraNunneryMD discusses findings from TROPION-Breast02 and what the data on Dato-DXd vs chemotherapy could mean for clinical practice in metastatic triple-negative breast cancer.

Watch the full discussion here 🔗 https://t.co/1KQZVzq18K

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Dr. Wade Iams, Director of Lung Cancer Research, discusses treatment sequencing after progression on a prior ROS1 inhibitor in ROS1+ NSCLC.

Watch the full discussion to learn more about treatment sequencing in ROS1-positive NSCLC. 🔗 https://t.co/pjpLQv6Qb2

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Dr. @SaraNunneryMD, Director of Breast Cancer Research, shares insights on choosing therapy beyond the first line in ESR1-mutated breast cancer, including the role of endocrine sensitivity, disease tempo, and patient-centered factors.

#BreastCancer #ESR1 #GHCR

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Dr. Wade Iams, Director of Lung Cancer Research, discusses key considerations when selecting frontline therapy for ROS1+ NSCLC, including progression-free survival.

Watch the full discussion: 🔗 https://t.co/B63NfyJJ3U

[Katy Beckermann @katy_beckermann]

We test FGFR3 to find a target. This meta-analysis pooled 13 cohorts and 2042 patients to show:
🧬 OS shorter with FGFR3 alterations: HR 1.25
📉 PFS HR 1.63 (1.23-2.16), disease control lower (RR 0.74)
📉ORR no different
⚖️ Limitations: retrospective, no non-ICI comparator

Why this matters for your practice: 💡 test up front, active trials using novel FGFR3 selective inhibitors in frontline ongoing!

#BladderCancer #UrothelialCancer #GUonc

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Dr. @WadeIams, Director of Lung Cancer Research, represented GHCR at #WCLC26 in Seoul! 🌎

Dr. Iams joined experts from around the world to share insights and discuss the latest advancements in lung cancer research and care.

#LungCancer #GHCR

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Twenty-five years later, we remember the lives lost on September 11, 2001, and honor the courage, sacrifice, and resilience shown that day.

Today and always, we remember.❤️

#NeverForget

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Dr. @WadeIams is attending #WCLC2026 this weekend in Seoul, where he’ll participate in several speaking engagements and events.

WCLC brings together global leaders to share the latest advances in lung cancer research and care.

Learn more 🔗 https://t.co/tEqmBzl9CA

#WCLC26

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Dr. Wade Iams, Director of Lung Cancer Research, joined Targeted Oncology to discuss transitioning from chemoimmunotherapy to targeted therapy when a ROS1 result becomes available in NSCLC.

Watch the full discussion: https://t.co/iYAqJC8VaB

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

This Labor Day, we recognize the dedication and hard work of our team and colleagues across the cancer research community who continue to move cancer care forward.

Wishing everyone a safe and restful Labor Day!

#LaborDay #GHCR #CancerResearch

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Dr. Wade Iams, Director of Lung Cancer Research, joined Targeted Oncology to discuss optimizing ROS1 testing in advanced NSCLC, including the role of RNA-based sequencing in identifying actionable gene fusions.

Watch the full discussion: https://t.co/2zMHCMVK2Y

[Greco-Hainsworth Centers for Research @GrecoHainsworth]

Please join us in welcoming our new Executive Director of Research to the Tennessee Oncology team, 𝐉𝐨𝐬𝐞𝐩𝐡 𝐇𝐢𝐧𝐞𝐬🎉

As a member of the GHCR team, he will join the work and dedicated research towards advancing care.

To learn more ➡️ https://t.co/2aB7kHBkqz